Synopsis : Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Tag:
nirsevimab
-
-
AstraZenecaPharma Science & Research
First RSV vaccine trial for infants offers significant results
by adminby adminSummary : Results from a phase 3 trial evaluating AstraZeneca and Sanofi’s jointly developed treatment nirsevimab – the first investigational long-acting antibody, designed to protect…